New pill could slow blindness in inherited eye disease

NCT ID NCT07408232

Ongoing Disease control Sponsor: Octant, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new oral drug called OCT-980 for people with a specific inherited eye disease (autosomal dominant retinitis pigmentosa) that causes gradual vision loss and blindness. The study first gives a single dose to healthy volunteers to check safety, then multiple doses to patients. The goal is to see if the drug is safe and can slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OCT-980 (oral capsule or tablet)
What this could lead to: If successful, this could point toward a treatment that slows or stops vision loss in people with a specific genetic form of retinitis pigmentosa.
What could go wrong: This is a very early, first-in-human trial with only 32 participants. The drug may not be safe or effective, and results may not apply to other forms of retinitis pigmentosa.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder retinitis pigmentosa retinitis pigmentosa 4

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Locations

CMAX Clinical Research Pty Ltd

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.